Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Int J Cancer. 2012 Apr 24;131(11):2562–2572. doi: 10.1002/ijc.27534

Figure 2.

Figure 2

Immunogenicity of death domain deficient hDR5 DNA vaccine constructs. A. Constructs of death domain deficient hDR5 DNA vaccines. B. Expression of recombinant hDR5 derivatives analyzed by flow cytometry after co-transfection of 3T3 cells with the test constructs and pEGFP. Control group was transfected with pEGFP alone. GFP positive cells were gated and cell surface expression of hDR5 was detected with mAb HS201 and PE-conjugated secondary antibody. The majority of GFP-positive transfected cells were also recognized by hDR5 mAb. C. Induction of hDR5-specific T cells. BALB/c mice were electrovaccinated 4 times as described (Material and Methods) with the indicated phDR5 constructs and pGM-CSF. Control group received blank vector (pVax1) and pGM-CSF (n=4-10). At two weeks after the 4th vaccination, T cell response was analyzed by IFN-γ ELISPOT using 3T3/hDKB or control 3T3/KB (n=3-4). *p<0.001 relative to pVax1. No significant differences between hDR5 vaccine groups were observed.